MFGE8 was more strongly expressed in patients with advanced grades of breast cancer (Figure 6a), and more specifically in the triple-negative HR-/HER2- subtype of these cancers (which are in majority of grade 3): 13/20 = 65% of triple-negative biopsies displayed MFGE8 levels ranked as 2 or 3, whereas only 5/36 = 13.8% of the hormone receptor (HR) and/or HER2 positive tumors displayed levels 2 or 3 of MFGE8 expression (Figure 6b). Here, NR4A1 is linked to cancer.